Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.62 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414963 | 0.96 | TLR7 (0.58) | TLR8TLR7CYP1A2CYP2D6L3MBTL1 | |
| SCHEMBL20219655 | 0.90 | TLR8 (0.50) | TLR8TLR7L3MBTL1 | |
| SCHEMBL23472442 | 0.89 | TLR8 (0.52) | TLR8TLR7L3MBTL1 | |
| SCHEMBL20219645 | 0.89 | TLR8 (0.51) | TLR8TLR7L3MBTL1 | |
| SCHEMBL17035550 | 0.88 | TLR7 (0.60) | TLR8TLR7CYP1A2L3MBTL1 | |
| SCHEMBL20219378 | 0.88 | TLR7 (0.52) | TLR8TLR7CYP2D6L3MBTL1 | |
| SCHEMBL20219510 | 0.86 | TLR8 (0.55) | TLR8TLR7L3MBTL1 | |
| SCHEMBL17035558 | 0.86 | TLR8 (0.54) | TLR8TLR7L3MBTL1 | |
| SCHEMBL20219632 | 0.85 | L3MBTL1 (0.48) | TLR8TLR7L3MBTL1 | |
| SCHEMBL23472257 | 0.85 | L3MBTL1 (0.58) | TLR8TLR7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-9284304-B2 | Substituted pyrimidines as toll-like receptor modulators | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-15 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239872-A1 | ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, PNP | TLR8 842/4885TLR7 437/4885CYP1A2 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.